These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 24309201)

  • 1. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F; Le Heuzey MF; Acquaviva E; Delorme R; Mouren MC
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
    Martinez-Raga J; Knecht C; Szerman N; Martinez MI
    CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ADHD pharmacotherapy: rates of stimulant use and cardiovascular risk.
    Kratochvil CJ
    Am J Psychiatry; 2012 Feb; 169(2):112-4. PubMed ID: 22318789
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR; Skimming JW; Muniz R
    Clin Pediatr (Phila); 2010 Sep; 49(9):840-51. PubMed ID: 20693523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Supervised off-label prescribing of methylphenidate in adult ADHD].
    Carton L; Dondaine T; Deheul S; Marquié C; Brigadeau F; Amad A; Devos D; Danel T; Bordet R; Cottencin O; Gautier S; Ménard O
    Encephale; 2019 Feb; 45(1):74-81. PubMed ID: 30122296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L; Bakker MJ; Banaschewski T; Carucci S; Coghill D; Danckaerts M; Dittmann RW; Hollis C; Kovshoff H; McCarthy S; Nagy P; Sonuga-Barke E; Wong IC; Zuddas A; Rosenthal E; Buitelaar JK;
    CNS Drugs; 2017 Mar; 31(3):199-215. PubMed ID: 28236285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Medication for ADHD and the risk of cardiovascular mortality].
    Langendijk PN; Wilde AA
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1713-4. PubMed ID: 16924941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do prescription stimulants increase the risk of adverse cardiovascular events?: A systematic review.
    Westover AN; Halm EA
    BMC Cardiovasc Disord; 2012 Jun; 12():41. PubMed ID: 22682429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD.
    Winterstein AG; Gerhard T; Shuster J; Saidi A
    Pediatrics; 2009 Jul; 124(1):e75-80. PubMed ID: 19564272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cardiovascular risk assessment for the use of ADHD drugs in children].
    Berg A; Bråtane E; Odland HH; Brudvik C; Rosland B; Hirth A
    Tidsskr Nor Laegeforen; 2014 Apr; 134(7):710-4. PubMed ID: 24721858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R; Germinario EA; Bonati M; Masi G; Zuddas A; Vella S; Chiarotti F; Panei P;
    J Child Adolesc Psychopharmacol; 2012 Dec; 22(6):423-431. PubMed ID: 23362511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encouraging news about ADHD drugs and heart risk in adults.
    Harv Ment Health Lett; 2012 Mar; 28(9):7. PubMed ID: 22474711
    [No Abstract]   [Full Text] [Related]  

  • 14. Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death.
    Knight M
    Pediatrics; 2007 Jan; 119(1):154-5. PubMed ID: 17200281
    [No Abstract]   [Full Text] [Related]  

  • 15. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function.
    Vitiello B
    Child Adolesc Psychiatr Clin N Am; 2008 Apr; 17(2):459-74, xi. PubMed ID: 18295156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on the safety of psychostimulants for the treatment of attention-deficit/hyperactivity disorder.
    Groenman AP; Schweren LJ; Dietrich A; Hoekstra PJ
    Expert Opin Drug Saf; 2017 Apr; 16(4):455-464. PubMed ID: 28277842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attention-deficit/hyperactivity disorder, stimulant therapy, and the patient with congenital heart disease: evidence and reason.
    Batra AS; Alexander ME; Silka MJ
    Pediatr Cardiol; 2012 Mar; 33(3):394-401. PubMed ID: 22298228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G; Besag FM
    Drug Saf; 2010 Oct; 33(10):821-42. PubMed ID: 20812768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA; Besag FM
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.